Table of Contents
On February 2, 2026, Piramal Pharma Solutions announced that it had commercialized a tablet-in-capsule drug delivery capability, following a five-month technology transfer from its development facility in Ahmedabad to its commercial manufacturing site in Pithampur, India. The capability enables the placement of distinct active pharmaceutical ingredients, formulated as separate tablets or minitablets with different release characteristics, into a single capsule.
The company said the system is intended for pharmaceutical developers working with more complex oral formulations, including modified or dual-release profiles and combinations of ingredients that cannot be co-formulated in a single matrix. Brad Gold, Head of Global Formulations R&D, said the approach can support formulation stability and allow multiple dosing requirements to be addressed within one capsule, potentially simplifying dosing regimens for patients. Piramal Pharma Solutions also highlighted the successful transfer from development to commercial scale as an example of coordination across its formulation and manufacturing sites.
In prior Onyx coverage, Piramal Pharma CEO Peter DeYoung described a strategic shift toward innovator-focused work, noting that this segment had grown to represent more than half of company sales, compared with a historical emphasis on off-patent lifecycle management. In that interview, DeYoung outlined a broader focus on differentiated capabilities and an integrated operating model spanning development and manufacturing, alongside a long-term financial framework referred to as “3-2-1,” defined as doubling revenue and tripling EBITDA.
You can read our previous interviews with Peter DeYoung, from March 2025.
Comments